Elza Márcia Targas Yacubian, Gerardo Maria de Araújo Filho
{"title":"特发性全身性癫痫患者的管理问题","authors":"Elza Márcia Targas Yacubian, Gerardo Maria de Araújo Filho","doi":"10.1016/j.epilep.2012.11.001","DOIUrl":null,"url":null,"abstract":"<div><p>Idiopathic generalized epilepsies (IGEs) are eight epilepsies defined in the 1989 ILAE Classification usually starting in childhood or adolescence. Since IGEs treatment is dependent on syndromic characterization, the clinical features are still the cornerstone of accurate classification and selection of appropriate treatment. We reviewed evidence-based data on treatment with antiepileptic drugs, as well as prognostic factors in IGEs. Evidence-based data support the use of valproate and ethosuximide in monotherapy for treatment of childhood absence epilepsy; topiramate in monotherapy for primarily generalized tonic–clonic seizures (PGTCS); and, as adjunctive therapy, of lamotrigine, levetiracetam and topiramate for PGTCS and levetiracetam for myoclonic seizures.</p></div>","PeriodicalId":100487,"journal":{"name":"Epileptology","volume":"1 1","pages":"Pages 1-10"},"PeriodicalIF":0.0000,"publicationDate":"2013-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.epilep.2012.11.001","citationCount":"7","resultStr":"{\"title\":\"Management issues for patients with idiopathic generalized epilepsies\",\"authors\":\"Elza Márcia Targas Yacubian, Gerardo Maria de Araújo Filho\",\"doi\":\"10.1016/j.epilep.2012.11.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Idiopathic generalized epilepsies (IGEs) are eight epilepsies defined in the 1989 ILAE Classification usually starting in childhood or adolescence. Since IGEs treatment is dependent on syndromic characterization, the clinical features are still the cornerstone of accurate classification and selection of appropriate treatment. We reviewed evidence-based data on treatment with antiepileptic drugs, as well as prognostic factors in IGEs. Evidence-based data support the use of valproate and ethosuximide in monotherapy for treatment of childhood absence epilepsy; topiramate in monotherapy for primarily generalized tonic–clonic seizures (PGTCS); and, as adjunctive therapy, of lamotrigine, levetiracetam and topiramate for PGTCS and levetiracetam for myoclonic seizures.</p></div>\",\"PeriodicalId\":100487,\"journal\":{\"name\":\"Epileptology\",\"volume\":\"1 1\",\"pages\":\"Pages 1-10\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.epilep.2012.11.001\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Epileptology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2212822012000051\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epileptology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212822012000051","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Management issues for patients with idiopathic generalized epilepsies
Idiopathic generalized epilepsies (IGEs) are eight epilepsies defined in the 1989 ILAE Classification usually starting in childhood or adolescence. Since IGEs treatment is dependent on syndromic characterization, the clinical features are still the cornerstone of accurate classification and selection of appropriate treatment. We reviewed evidence-based data on treatment with antiepileptic drugs, as well as prognostic factors in IGEs. Evidence-based data support the use of valproate and ethosuximide in monotherapy for treatment of childhood absence epilepsy; topiramate in monotherapy for primarily generalized tonic–clonic seizures (PGTCS); and, as adjunctive therapy, of lamotrigine, levetiracetam and topiramate for PGTCS and levetiracetam for myoclonic seizures.